LWANC
VIR icon

Laurel Wealth Advisors (North Carolina)’s Vir Biotechnology VIR Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-225
Closed -$6K – 677
2020
Q4 		$6K Buy
+225
New +$7.31K ﹤0.01% 465

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.28B AUM 16.36% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s VIR Position: Q1 2021 in Review

Laurel Wealth Advisors (North Carolina) sold out of Vir Biotechnology (VIR) in Q1 2021, closing a stake of 225 shares — an estimated $6K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in VIR in Q4 2020 and held it in 1 quarter. The position peaked at $6K in Q4 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Vir Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 225 Vir Biotechnology shares in Q1 2021, an estimated $6K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Vir Biotechnology in Q4 2020 and held it in 1 quarter.
  • Laurel Wealth Advisors (North Carolina)'s Vir Biotechnology position peaked at $6K in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2021, filed 4 May 2021.